BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vargas-díez E, García-díez A, Marín A, Fernández-herrera J. Life-threatening graft-vs-host disease. Clinics in Dermatology 2005;23:285-300. [DOI: 10.1016/j.clindermatol.2004.06.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Le Bastard Q, Chevallier P, Montassier E. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease. World J Gastroenterol 2021; 27(45): 7792-7800 [PMID: 34963742 DOI: 10.3748/wjg.v27.i45.7792] [Reference Citation Analysis]
2 Travnik R, Beckers M, Wolff D, Holler E, Landthaler M, Karrer S. [Graft-versus-host disease (GvHD) - an update. Part 2: prognosis and therapy of GvHD]. Hautarzt 2011;62:229-37; quiz 238-9. [PMID: 21308356 DOI: 10.1007/s00105-010-2118-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Oelkrug C, Sack U, Boldt A, Nascimento IC, Ulrich H, Fricke S. Antibody- and aptamer-strategies for GvHD prevention. J Cell Mol Med 2015;19:11-20. [PMID: 25353670 DOI: 10.1111/jcmm.12416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Cheng J, Zhou Y, Chen B, Wang J, Xia G, Jin N, Ding J, Gao C, Chen G, Miao Y, Li W, Liu Z, Wang X. Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe₃O₄ combined with cyclosporin A in murine models. Int J Nanomedicine 2011;6:2183-9. [PMID: 22114482 DOI: 10.2147/IJN.S24567] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Carcagnì MR, De Aloe G, D'Ascenzo G, Rubegni P, Fimiani M. Extracorporeal photopheresis in graft-versus-host disease. J Dtsch Dermatol Ges 2008;6:451-7. [PMID: 18177413 DOI: 10.1111/j.1610-0387.2007.06591.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kragelund C, Hansen C, Reibel J, Nauntofte B, Brosen K, Jensen SB, Torpet L. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?: Oral lichenoid drug eruptions and impaired CYP activity. Journal of Oral Pathology & Medicine 2010;39:497-505. [DOI: 10.1111/j.1600-0714.2010.00897.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
7 Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heußner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 2013;22:1509-16. [PMID: 22945857 DOI: 10.1002/pon.3159] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
8 Paice JA. Chronic treatment-related pain in cancer survivors. Pain 2011;152:S84-9. [PMID: 21036475 DOI: 10.1016/j.pain.2010.10.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
9 Goiriz R, Peñas P, Delgado-jiménez Y, Fernández-herrera J, Aragüés-montañés M, Fraga J, García-díez A. Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus. Lupus 2008;17:591-5. [DOI: 10.1177/0961203307087874] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
10 Villa NY, Rahman MM, McFadden G, Cogle CR. Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses 2016;8:85. [PMID: 27011200 DOI: 10.3390/v8030085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Quellmann S, Schwarzer G, Hübel K, Greb A, Engert A, Bohlius J. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. Cochrane Database Syst Rev 2008;:CD004885. [PMID: 18646116 DOI: 10.1002/14651858.CD004885.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
12 Vaidya T, Menzer C, Ponce DM, Markova A. Inpatient Management of Mucocutaneous GVHD. Curr Dermatol Rep 2019;8:258-78. [PMID: 33312761 DOI: 10.1007/s13671-019-00280-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Lynch B, Paice JA. Pain and Palliative Care Needs of Cancer Survivors: . Journal of Hospice & Palliative Nursing 2011;13:202-7. [DOI: 10.1097/njh.0b013e318220be18] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Naserian S, Leclerc M, Shamdani S, Uzan G. Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. Front Immunol 2020;11:607030. [PMID: 33391276 DOI: 10.3389/fimmu.2020.607030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lutz M, Kapp M, Einsele H, Grigoleit GU, Mielke S. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. Clin Transplant 2014;28:1410-5. [DOI: 10.1111/ctr.12472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Thiruvenkatarajan V, Rebecca J. Anesthesia and graft-vs-host disease after hematopoietic stem cell transplantation. Paediatr Anaesth 2007;17:7-15. [PMID: 17184425 DOI: 10.1111/j.1460-9592.2006.02057.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. Journal of the American Academy of Dermatology 2007;56:181-200. [DOI: 10.1016/j.jaad.2006.04.048] [Cited by in Crossref: 198] [Cited by in F6Publishing: 143] [Article Influence: 13.2] [Reference Citation Analysis]
18 Peñas PF, Zaman S. Many faces of graft- versus -host disease. Australasian Journal of Dermatology 2010;51:1-10. [DOI: 10.1111/j.1440-0960.2009.00577.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
19 Villarreal CD, Alanis JC, Pérez JC, Candiani JO. Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review. An Bras Dermatol 2016;91:336-43. [PMID: 27438202 DOI: 10.1590/abd1806-4841.20164180] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
20 Silvana B, Antonella LM, Basilia P, Trombetta D, Saija A, Salpietro C. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome. Pediatr Transplant 2007;11:552-6. [PMID: 17631027 DOI: 10.1111/j.1399-3046.2007.00678.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Delgado-jimenez Y, Goiriz R, Vargas-diez E, Fraga J, Garcia-diez A, Fernandez-herrera J. Acute graft-versus-host disease (GVHD) overlapping chronic GVHD after reinduction chemotherapy. Br J Dermatol 2007;156:388-90. [DOI: 10.1111/j.1365-2133.2006.07630.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Ramakrishnaiah PK, Lakshman A, Aradhya SS, Veerabhadrappa NH. Lichenoid Variant of Chronic Cutaneous Graft Versus Host Reaction Post Blood Transfusion: A Rare Event Post Blood Transfusion. Indian J Dermatol 2015;60:525. [PMID: 26538747 DOI: 10.4103/0019-5154.159667] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Santos E Sousa P, Bennett CL, Chakraverty R. Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease. Front Immunol 2018;9:963. [PMID: 29770141 DOI: 10.3389/fimmu.2018.00963] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]